Oncology (all articles)
RCT | Perioperative nivolumab plus chemotherapy increases pathological response vs. chemotherapy alone in stage III NSCLC
10 Jul, 2023 | 13:27h | UTCPerioperative Nivolumab and Chemotherapy in Stage III Non–Small-Cell Lung Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Addition of Neoadjuvant Nivolumab to Platinum-Based Chemotherapy in Stage III NSCLC – The ASCO Post
Commentary on Twitter
Original Article: Perioperative Nivolumab and Chemotherapy in Stage III Non–Small-Cell Lung Cancer https://t.co/DCcs0tkyPN #oncology pic.twitter.com/0zG9SUbqQj
— NEJM (@NEJM) June 30, 2023
RCT | Brachytherapy alone sufficient for intermediate-risk prostate cancer, no FFP improvement with additional EBRT
7 Jul, 2023 | 16:06h | UTCEffect of Brachytherapy With External Beam Radiation Therapy Versus Brachytherapy Alone for Intermediate-Risk Prostate Cancer: NRG Oncology RTOG 0232 Randomized Clinical Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)
RCT | FOLFOXIRI-Bevacizumab shows promise as first-line treatment in unresectable colorectal cancer metastases
5 Jul, 2023 | 01:02h | UTCFirst-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group – The Lancet Oncology (link to abstract – $ for full-tetxt)
Scoping Review | High correlation of positive outcomes in oncology meta-analyses with industry funding
3 Jul, 2023 | 14:21h | UTC
Consensus Paper | Colorectal neuroendocrine tumors
30 Jun, 2023 | 14:45h | UTC
SR | Drivers of emergency department use among oncology patients in the era of novel cancer therapeutics
30 Jun, 2023 | 14:35h | UTC
FIGO staging of endometrial cancer: 2023
29 Jun, 2023 | 13:53h | UTCFIGO staging of endometrial cancer: 2023 – Gynecology & Obstetrics
Perspective | Ensuring ethical postprogression therapy for patients in randomized trial control arms
28 Jun, 2023 | 13:16h | UTC
Commentary on Twitter
Ensuring Ethical Postprogression Therapy for Patients in RCT Arms
"Patients participating in clinical trials make significant sacrifices, and in return the academic and clinical communities owe them optimal treatment after progression"@JCO_ASCO https://t.co/2dv2rky2WN pic.twitter.com/rQfRx3T4Ii
— Yakup Ergün (@dr_yakupergun) June 22, 2023
RCT | Total breast reconstruction with autologous fat transfer using an expansion device vs implants in patients with breast cancer
28 Jun, 2023 | 13:12h | UTCEffect of Total Breast Reconstruction With Autologous Fat Transfer Using an Expansion Device vs Implants on Quality of Life Among Patients With Breast Cancer: A Randomized Clinical Trial – JAMA Surgery (link to abstract – $ for full-text)
See also: Visual Abstract
Author Interview: Effect of Breast Reconstruction With Autologous Fat Transfer vs Implants on Quality of Life – JAMA
SR | Medically assisted hydration in palliative care: uncertain effects on quality of life and survival
27 Jun, 2023 | 13:47h | UTCSummary: The Cochrane Review analyzed Randomized Controlled Trials (RCTs) to evaluate the impact of Medically Assisted Hydration (MAH) on the Quality of Life (QoL) and survival of adults receiving palliative care. A total of four studies involving 422 participants, all diagnosed with advanced cancer, were considered. Two studies compared MAH with placebo, and two compared it with standard care.
The primary outcome was QoL, assessed through validated scales, with survival and adverse events being secondary outcomes. Mean differences (MD) and risk ratios (RR) were calculated for continuous and dichotomous outcomes, respectively. However, results were inconclusive due to a very low certainty of evidence. Hence, it is unclear whether MAH improves QoL, prolongs survival, or leads to adverse events when compared to placebo or standard care.
The findings are only applicable to inpatients with advanced cancer at the end of life and do not transfer to other adults in palliative care with non-cancer, dementia, or neurodegenerative diseases, or those with an extended prognosis. The lack of high-quality evidence leaves clinicians to make decisions based on perceived benefits and harms for individual circumstances.
Article: Medically assisted hydration for adults receiving palliative care – Cochrane Library
M-A | Effectiveness of physical therapy in axillary web syndrome after breast cancer
27 Jun, 2023 | 13:28h | UTC
Perspective | Early-stage lung cancer: using circulating tumor DNA to get personal
26 Jun, 2023 | 00:38h | UTCEarly-Stage Lung Cancer: Using Circulating Tumor DNA to Get Personal – Journal of Clinical Oncology
Review | How to treat diffuse large B-cell lymphoma: oncologic and cardiovascular considerations
26 Jun, 2023 | 00:33h | UTC
Commentary on Twitter
Are you struggling w/ how to protect patients w/ #DLBCL & CV comorbidities from #anthracycline #cardiotoxicity?
Follow this simple "how to guide" to cardioprotection by Dr. @SwethaKamMD et al in #JACCCardioOnc: https://t.co/d07eqOcB6V#lymphoma #CardioOnc #lymsm #CardioTwitter pic.twitter.com/W33FHjwA63
— JACC Journals (@JACCJournals) June 22, 2023
Clinical insights into small cell lung cancer: tumor heterogeneity, diagnosis, therapy, and future directions
26 Jun, 2023 | 00:31h | UTC
Review | Treatment options in HER2-low breast cancer and proposed treatment sequencing algorithm
26 Jun, 2023 | 00:27h | UTC
Cohort Study | Adiposity impacts cancer risk differently in males and females
22 Jun, 2023 | 15:08h | UTCAdiposity and sex-specific cancer risk – Cancer Cell
News Release: Cancer has an obesity-related risk factor, and it depends on sex and cancer type – Cell Press
Cohort Study | Steady reduction in breast cancer mortality from 1993-2015 in England
22 Jun, 2023 | 14:58h | UTCInvited Commentary: Risk of breast cancer death after a diagnosis of early invasive breast cancer – The BMJ
Commentary on Twitter
NEW research finds that most women diagnosed with early breast cancer can expect to become long term cancer survivors https://t.co/TaYqRJD6Lu pic.twitter.com/V15bLdmI2H
— The BMJ (@bmj_latest) June 14, 2023
Updated Guidance | Diagnosis and treatment of Early and locally advanced breast cancer
22 Jun, 2023 | 14:52h | UTC
ESTRO-ACROP guideline | Recommendations on implementation of breath-hold techniques in radiotherapy
22 Jun, 2023 | 14:51h | UTC
SR | Supportive care interventions for managing gastrointestinal symptoms following treatment for colorectal cancer
22 Jun, 2023 | 14:49h | UTC
Cohort Study | Stopping immunotherapy in patients that are progression-free at 2 years seems feasible in advanced NSCLC
21 Jun, 2023 | 13:19h | UTCAssociation Between Duration of Immunotherapy and Overall Survival in Advanced Non–Small Cell Lung Cancer – JAMA Oncology (link to abstract – $ for full-text)
Commentary on Twitter
Study of patients with #NSCLC showed no survival difference between 2-yr fixed duration vs indefinite #immunotherapy, suggesting that IO can be d/c at 2 yrs. @PennCancer @flatironhealth @lovasunMD @Ron_cology @CharuAggarwalMD #ASCO23 https://t.co/EWyneghc8a pic.twitter.com/HkyIwwtJiM
— JAMA Oncology (@JAMAOnc) June 4, 2023
RCT | Fruquintinib extends median survival to 7.4 months vs. 4.8 months with placebo in refractory metastatic colorectal cancer
19 Jun, 2023 | 14:02h | UTCFruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study – The Lancet (link to abstract – $ for full-text)
Commentary on Twitter questioning the control group (thread – click for more)
Disgusting, unethical PLACEBO control trial in colon cancer just so Fruquitinib can win
I will show you that placebo should not have been the control arm, & the IRBs & FDA failed ?
First, this trial tests a new drug vs. placebo (sugar pill) in patients dying of colon cancer pic.twitter.com/fa915vgUbp
— Vinay Prasad MD MPH (@VPrasadMDMPH) June 17, 2023
Review | mRNA-based cancer therapeutics
19 Jun, 2023 | 13:53h | UTCmRNA-based cancer therapeutics – Nature Reviews Cancer
Commentary on Twitter
Excited to share our paper entitled "mRNA-based cancer therapeutics" @NatureRevCancer. Congrats to all the group members @BrighamWomens @harvardmed on this paper! ?https://t.co/1LB1M1Yl96https://t.co/QwmDZmyixB
— Wei Tao (@WeiTaoLab) June 13, 2023
RCT | Cisplatin–gemcitabine improves 3-year progression-free survival in N2–3 nasopharyngeal carcinoma compared to cisplatin–fluorouracil
16 Jun, 2023 | 14:05h | UTCConcurrent chemoradiotherapy followed by adjuvant cisplatin–gemcitabine versus cisplatin–fluorouracil chemotherapy for N2–3 nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentary on Twitter
NOW OF: Concurrent chemoradiotherapy followed by adjuvant cisplatin–gemcitabine versus cisplatin–fluorouracil chemotherapy for N2–3 nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trialhttps://t.co/n6WalQiRfo pic.twitter.com/vE4VASUIgM
— The Lancet Oncology (@TheLancetOncol) June 5, 2023
RCT | Increased detection of metastases via PET-CT alters treatment path in locally advanced breast cancer
16 Jun, 2023 | 14:02h | UTCImpact of 18F-Labeled Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography Versus Conventional Staging in Patients With Locally Advanced Breast Cancer – Journal of Clinical Oncology (link to abstract – $ for full-text)